gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Inner membrane protein, mitochondrial

SV2, SV2A, p89
Top mentioned proteins: CAN, Synaptophysin, HAD, ACID, CD45
Papers using SV2 antibodies
Muscle activity and muscle agrin regulate the organization of cytoskeletal proteins and attached acetylcholine receptor (AChR) aggregates in skeletal muscle fibers
Abe Koji et al., In Neurology International, 2000
... The following primary antibodies were used: anti-SV2 (sc-11936, Santa Cruz Biotechnology, CA, USA), anti-agrin (MAB5204, ...
Papers on SV2
Brivaracetam for the treatment of epilepsy.
Rektor et al., Bethesda, United States. In Expert Opin Pharmacother, Feb 2016
Levetiracetam is an effective antiepileptic drug (AED) postulated to act by binding to synaptic vesicle protein 2A.
Actions of Bisphenol A and Bisphenol S on the Reproductive Neuroendocrine System During Early Development in Zebrafish.
Wayne et al., Shanghai, China. In Endocrinology, Jan 2016
Environmentally relevant, low levels of BPA exposure during development led to advanced hatching time, increased numbers of Gonadotropin-Releasing Hormone 3 (GnRH3) neurons in both terminal nerve and hypothalamus, increased expression of reproduction-related genes (kiss1, kiss1r, gnrh3, lhβ, fshβ, and erα) and a marker for synaptic transmission (sv2).
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Klitgaard et al., Braine-le-Comte, Belgium. In Epilepsia, Jan 2016
The preclinical studies described here investigated the high-affinity synaptic vesicle glycoprotein 2A (SV2A) antiepileptic drug brivara-cetam (BRV) for its rate of brain penetration and its onset of action.
Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A.
Coffield et al., Taiyuan, China. In Plos One, Dec 2015
RESULTS: 1) Three-week-old cultured dorsal root ganglion neurons highly expressed transient TRPV1, synaptic vesicle 2A (SV2A) and synaptosomal-associated protein 25 (SNAP-25).
A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
Müller et al., Frankfurt am Main, Germany. In J Alzheimers Dis, Dec 2015
We demonstrate for the first time, using immunohistochemistry and proteomics, that the synaptic vesicle protein 2A (SV2a), the molecular target of levetiracetam, is expressed in mitochondria.
Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.
Russo et al., Napoli, Italy. In Expert Opin Pharmacother, 2014
Furthermore, for some of these (e.g., lacosamide and eslicarbazepine) data are already available from post-marketing studies while brivaracetam acting on SV2A like levetiracetam might have the same potential effectiveness with the possibility to be more efficacious considering its ability to inhibit voltage gated sodium channels; finally, perampanel and retigabine are very effective drugs in animal models of TLE.
Generation of Functional Neuromuscular Junctions from Human Pluripotent Stem Cell Lines.
Koistinaho et al., Kuopio, Finland. In Front Cell Neurosci, 2014
Neurons formed end plate like structures with strong binding of α-bungarotoxin, a marker of nicotinic acetylcholine receptors highly expressed in the postsynaptic membrane of NMJs, and expressed SMI-32, a motoneuron marker, as well as SV2, a marker for synapses.
Brivaracetam for the treatment of epilepsy in adults.
Mula, London, United Kingdom. In Expert Rev Neurother, 2014
Brivaracetam (BRV) is a new antiepileptic drug structurally related to levetiracetam but with a 15 to 30-fold increased affinity for the same molecular target, namely the SV2A ligand.
Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A.
Kammerer et al., China. In Nature, 2014
Two types of BoNT/A receptor have been identified, both of which are required for BoNT/A toxicity and are therefore likely to cooperate with each other: gangliosides and members of the synaptic vesicle glycoprotein 2 (SV2) family, which are putative transporter proteins that are predicted to have 12 transmembrane domains, associate with the receptor-binding domain of the toxin.
Structure activity relationships of novel antiepileptic drugs.
Roberts et al., Los Angeles, United States. In Curr Med Chem, 2013
The synaptic vesicle glycoprotein 2A (SV2A), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) and voltage-gated potassium channels (KCNQ2/Q3) are clinically validated as new molecular targets for epilepsy.
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease.
Abeliovich et al., New York City, United States. In Nature, 2013
Several of these--including APBA2, FYN, RNF219 and SV2A--encode known or novel modulators of LOAD associated amyloid beta A4 precursor protein (APP) endocytosis and metabolism.
Prospects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and stroke.
Shetty, Temple, United States. In Front Neurol, 2012
In addition to its neuromodulatory and neuroinhibitory effects via its binding to the synaptic vesicle protein SV2A, multiple studies have suggested neuroprotective properties for LEV in both epileptic and non-epileptic conditions.
Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration.
Bahn et al., Cambridge, United Kingdom. In J Proteome Res, 2012
A protein encoded by this locus was found to be differentially expressed in postmortem brains from patients with atypical frontotemporal lobar degeneration.
CHCM1/CHCHD6, novel mitochondrial protein linked to regulation of mitofilin and mitochondrial cristae morphology.
Sheikh et al., Syracuse, United States. In J Biol Chem, 2012
CHCM1/CHCHD6, novel mitochondrial protein linked to regulation of mitofilin and mitochondrial cristae morphology.
Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus.
Sasa et al., Takatsuki, Japan. In Neurosci Lett, 2012
study suggests that SV2A specifically regulates hilar GABAergic neurotransmission in the kindled hippocampus probably as a compensatory or prophylactic mechanism against kindling epileptogenesis
Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
Lebon et al., Slough, United Kingdom. In Biochem Soc Trans, 2011
Data report a combined modelling and mutagenesis study that successfully identifies another 11 residues in synaptic vesicle protein 2A that appear to be involved in ligand binding.
Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
Reijneveld et al., Amsterdam, Netherlands. In Neurology, 2011
expression of SV2A in tumor and peritumoral tissue is correlated to the clinical response to levetiracetam and predicts levetiracetam efficacy
SV2 is the protein receptor for botulinum neurotoxin A.
Chapman et al., Madison, United States. In Science, 2006
findings show that botulinum neurotoxin (BoNT/A) enters neurons by binding to the synaptic vesicle protein SV2 (isoforms A, B, and C);SV2 acts as the protein receptor for BoNT/A
SV2 modulates the size of the readily releasable pool of secretory vesicles.
Bajjalieh et al., Seattle, United States. In Nat Cell Biol, 2001
Here we show that Synaptic Vesicle Protein 2 (SV2), a protein specific to neurons and endocrine cells, is required to maintain a pool of vesicles available for calcium-stimulated exocytosis.
A role for synaptotagmin (p65) in regulated exocytosis.
Scheller et al., Stanford, United States. In Cell, 1993
Antibodies raised against the cytoplasmic domains of five of these proteins, vamp, rab3A, synaptophysin, synaptotagmin, and SV2, were used to investigate their function.
share on facebooktweetadd +1mail to friends